Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada A, Jacob AT, Kinahan C, Francescone MM, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes D, Scotto L, Sokol L, Shustov AR, O'Connor OA. Falchi L, et al. Blood. 2021 Apr 22;137(16):2161-2170. doi: 10.1182/blood.2020009004. Blood. 2021. PMID: 33171487 Free article. Clinical Trial.
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.
Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, Khan K, Atkins L, Rada A, Kim HA, Chiuzan C, Kalac M, Marchi E, Falchi L, Francescone MA, Schwartz L, Cremers S, O'Connor OA. Amengual JE, et al. Among authors: falchi l. Blood. 2018 Jan 25;131(4):397-407. doi: 10.1182/blood-2017-09-806737. Epub 2017 Nov 15. Blood. 2018. PMID: 29141948 Free PMC article. Clinical Trial.
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.
O'Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual JE, Kim HA, Rada AM, Khan K, Jacob AT, Malanga M, Francescone MM, Nandakumar R, Soderquist CR, Park DC, Bhagat G, Cheng B, Risueño A, Menezes D, Shustov AR, Sokol L, Scotto L. O'Connor OA, et al. Among authors: falchi l. Blood. 2019 Oct 24;134(17):1395-1405. doi: 10.1182/blood.2019001285. Blood. 2019. PMID: 31471376 Free article. Clinical Trial.
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways.
Scotto L, Kinahan C, Douglass E, Deng C, Safari M, Casadei B, Marchi E, Lue JK, Montanari F, Falchi L, Qiao C, Renu N, Bates SE, Califano A, O'Connor OA. Scotto L, et al. Among authors: falchi l. Mol Cancer Ther. 2021 Aug;20(8):1422-1430. doi: 10.1158/1535-7163.MCT-20-0377. Epub 2021 Jun 9. Mol Cancer Ther. 2021. PMID: 34108263 Free PMC article.
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J. O'Connor OA, et al. Among authors: falchi l. Lancet Oncol. 2018 Feb;19(2):257-266. doi: 10.1016/S1470-2045(17)30912-9. Epub 2017 Dec 21. Lancet Oncol. 2018. PMID: 29276022 Free PMC article. Clinical Trial.
Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.
Sha F, Okwali M, Alperovich A, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Khan N, Kumar A, Matasar MJ, Moskowitz AJ, Noy A, Owens C, Palomba LM, Rodriguez-Rivera I, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Schöder H, Seshan VE, Salles G, Younes A, Batlevi CL. Sha F, et al. Among authors: falchi l. Blood Cancer J. 2022 Feb 10;12(2):29. doi: 10.1038/s41408-022-00620-w. Blood Cancer J. 2022. PMID: 35145059 Free PMC article.
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.
Sermer D, Bobillo S, Dogan A, Zhang Y, Seshan V, Lavery JA, Batlevi C, Caron P, Hamilton A, Hamlin P, Horwitz S, Joffe E, Kumar A, Matasar M, Noy A, Owens C, Moskowitz A, Palomba ML, Straus D, von Keudell G, Rodriguez-Rivera I, Falchi L, Zelenetz A, Yahalom J, Younes A. Sermer D, et al. Among authors: falchi l. Blood Adv. 2020 Jul 28;4(14):3382-3390. doi: 10.1182/bloodadvances.2020001551. Blood Adv. 2020. PMID: 32722781 Free PMC article.
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies.
Sermer D, Batlevi C, Palomba ML, Shah G, Lin RJ, Perales MA, Scordo M, Dahi P, Pennisi M, Afuye A, Silverberg ML, Ho C, Flynn J, Devlin S, Caron P, Hamilton A, Hamlin P, Horwitz S, Joffe E, Kumar A, Matasar M, Noy A, Owens C, Moskowitz A, Straus D, von Keudell G, Rodriguez-Rivera I, Falchi L, Zelenetz A, Yahalom J, Younes A, Sauter C. Sermer D, et al. Among authors: falchi l. Blood Adv. 2020 Oct 13;4(19):4669-4678. doi: 10.1182/bloodadvances.2020002118. Blood Adv. 2020. PMID: 33002134 Free PMC article.
114 results